INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 300 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $29,102,638 | -22.3% | 920,387 | +0.2% | 0.01% | -14.3% |
Q2 2023 | $37,457,327 | +32.0% | 918,522 | +20.6% | 0.01% | +16.7% |
Q1 2023 | $28,380,732 | +5.7% | 761,490 | -1.1% | 0.01% | 0.0% |
Q4 2022 | $26,860,415 | -31.9% | 769,860 | +9.2% | 0.01% | -33.3% |
Q3 2022 | $39,439,000 | +8.2% | 704,774 | +0.1% | 0.01% | +12.5% |
Q2 2022 | $36,442,000 | -27.3% | 704,057 | +2.1% | 0.01% | -11.1% |
Q1 2022 | $50,114,000 | -42.6% | 689,611 | -6.5% | 0.01% | -35.7% |
Q4 2021 | $87,239,000 | -12.6% | 737,803 | -0.8% | 0.01% | -22.2% |
Q3 2021 | $99,770,000 | -12.9% | 743,718 | +5.1% | 0.02% | -10.0% |
Q2 2021 | $114,518,000 | +121.3% | 707,297 | +9.7% | 0.02% | +100.0% |
Q1 2021 | $51,750,000 | +48.2% | 644,821 | +0.5% | 0.01% | +42.9% |
Q4 2020 | $34,919,000 | +169.6% | 641,907 | -1.5% | 0.01% | +133.3% |
Q3 2020 | $12,950,000 | +30.6% | 651,407 | +38.1% | 0.00% | +50.0% |
Q2 2020 | $9,914,000 | +58.6% | 471,632 | -7.7% | 0.00% | 0.0% |
Q1 2020 | $6,249,000 | -15.2% | 510,891 | +1.7% | 0.00% | 0.0% |
Q4 2019 | $7,370,000 | +12.4% | 502,410 | +2.3% | 0.00% | 0.0% |
Q3 2019 | $6,559,000 | -1.8% | 491,294 | +20.4% | 0.00% | 0.0% |
Q2 2019 | $6,678,000 | -0.8% | 407,948 | +3.5% | 0.00% | 0.0% |
Q1 2019 | $6,733,000 | +26.5% | 394,211 | +1.1% | 0.00% | +100.0% |
Q4 2018 | $5,322,000 | -52.8% | 389,930 | -1.0% | 0.00% | -66.7% |
Q3 2018 | $11,269,000 | +13.1% | 393,769 | +8.1% | 0.00% | 0.0% |
Q2 2018 | $9,963,000 | +155.9% | 364,171 | +97.3% | 0.00% | +200.0% |
Q1 2018 | $3,894,000 | +10.8% | 184,618 | +1.0% | 0.00% | 0.0% |
Q4 2017 | $3,514,000 | -7.1% | 182,836 | +20.2% | 0.00% | 0.0% |
Q3 2017 | $3,781,000 | +546.3% | 152,159 | +315.8% | 0.00% | – |
Q2 2017 | $585,000 | -45.6% | 36,596 | -52.0% | 0.00% | – |
Q1 2017 | $1,075,000 | +5.2% | 76,295 | -2.1% | 0.00% | – |
Q4 2016 | $1,022,000 | -20.3% | 77,959 | +3.4% | 0.00% | – |
Q3 2016 | $1,283,000 | -20.6% | 75,396 | -0.4% | 0.00% | -100.0% |
Q2 2016 | $1,615,000 | – | 75,683 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |